Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010

Jien Wei Liu; Wen Chien Ko; Cheng Hua Huang; Chun Hsing Liao; Chin Te Lu; Yin Ching Chuang; Shih Ming Tsao; Yao Shen Chen; Yung Ching Liu; Wei Yu Chen; Tsrang Neng Jang; Hsiu Chen Lin; Chih Ming Chen; Zhi Yuan Shi; Sung Ching Pan; Jia Ling Yang; Hsiang Chi Kung; Chun Eng Liu; Yu Jen Cheng; Yen Hsu Chen; Po Liang Lu; Wu Sun; Lih Shinn Wang; Kwok Woon Yu; Ping Cherng Chiang; Ming Hsun Lee; Chun Ming Lee; Gwo Jong Hsu; Po Ren Hsueh

doi:10.1128/AAC.05879-11

Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010

Jien Wei Liu, Wen Chien Ko, Cheng Hua Huang, Chun Hsing Liao, Chin Te Lu, Yin Ching Chuang, Shih Ming Tsao, Yao Shen Chen, Yung Ching Liu, Wei Yu Chen, Tsrang Neng Jang, Hsiu Chen Lin, Chih Ming Chen, Zhi Yuan Shi, Sung Ching Pan, Jia Ling Yang, Hsiang Chi Kung, Chun Eng Liu, Yu Jen Cheng, Yen Hsu ChenPo Liang Lu, Wu Sun, Lih Shinn Wang, Kwok Woon Yu, Ping Cherng Chiang, Ming Hsun Lee, Chun Ming Lee, Gwo Jong Hsu, Po Ren Hsueh

內科學科

研究成果: Article › 同行評審

29 引文斯高帕斯（Scopus）

摘要

The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC ₉₀ values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were <5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.

原文	English
頁（從 - 到）	1414-1417
頁數	4
期刊	Antimicrobial agents and chemotherapy
卷	56
發行號	3
DOIs	https://doi.org/10.1128/AAC.05879-11
出版狀態	Published - 2012 3月

All Science Journal Classification (ASJC) codes

藥理
藥學（醫學）
傳染性疾病

存取文件

10.1128/AAC.05879-11

其它文件與鏈接

指紋

深入研究「Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010」主題。共同形成了獨特的指紋。

引用此

Liu, J. W., Ko, W. C., Huang, C. H., Liao, C. H., Lu, C. T., Chuang, Y. C., Tsao, S. M., Chen, Y. S., Liu, Y. C., Chen, W. Y., Jang, T. N., Lin, H. C., Chen, C. M., Shi, Z. Y., Pan, S. C., Yang, J. L., Kung, H. C., Liu, C. E., Cheng, Y. J., ... Hsueh, P. R. (2012). Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. Antimicrobial agents and chemotherapy, 56(3), 1414-1417. https://doi.org/10.1128/AAC.05879-11

Liu, Jien Wei ; Ko, Wen Chien ; Huang, Cheng Hua 等. / Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates : Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. 於: Antimicrobial agents and chemotherapy. 2012 ; 卷 56, 編號 3. 頁 1414-1417.

@article{b41aaab262854c59a2d9989bdf14820b,

title = "Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010",

abstract = "The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were <5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.",

author = "Liu, {Jien Wei} and Ko, {Wen Chien} and Huang, {Cheng Hua} and Liao, {Chun Hsing} and Lu, {Chin Te} and Chuang, {Yin Ching} and Tsao, {Shih Ming} and Chen, {Yao Shen} and Liu, {Yung Ching} and Chen, {Wei Yu} and Jang, {Tsrang Neng} and Lin, {Hsiu Chen} and Chen, {Chih Ming} and Shi, {Zhi Yuan} and Pan, {Sung Ching} and Yang, {Jia Ling} and Kung, {Hsiang Chi} and Liu, {Chun Eng} and Cheng, {Yu Jen} and Chen, {Yen Hsu} and Lu, {Po Liang} and Wu Sun and Wang, {Lih Shinn} and Yu, {Kwok Woon} and Chiang, {Ping Cherng} and Lee, {Ming Hsun} and Lee, {Chun Ming} and Hsu, {Gwo Jong} and Hsueh, {Po Ren}",

year = "2012",

month = mar,

doi = "10.1128/AAC.05879-11",

language = "English",

volume = "56",

pages = "1414--1417",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

Liu, JW, Ko, WC, Huang, CH, Liao, CH, Lu, CT, Chuang, YC, Tsao, SM, Chen, YS, Liu, YC, Chen, WY, Jang, TN, Lin, HC, Chen, CM, Shi, ZY, Pan, SC, Yang, JL, Kung, HC, Liu, CE, Cheng, YJ, Chen, YH, Lu, PL, Sun, W, Wang, LS, Yu, KW, Chiang, PC, Lee, MH, Lee, CM, Hsu, GJ & Hsueh, PR 2012, 'Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010', Antimicrobial agents and chemotherapy, 卷 56, 編號 3, 頁 1414-1417. https://doi.org/10.1128/AAC.05879-11

Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. / Liu, Jien Wei; Ko, Wen Chien; Huang, Cheng Hua 等.
於: Antimicrobial agents and chemotherapy, 卷 56, 編號 3, 03.2012, p. 1414-1417.

研究成果: Article › 同行評審

TY - JOUR

T1 - Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates

T2 - Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010

AU - Liu, Jien Wei

AU - Ko, Wen Chien

AU - Huang, Cheng Hua

AU - Liao, Chun Hsing

AU - Lu, Chin Te

AU - Chuang, Yin Ching

AU - Tsao, Shih Ming

AU - Chen, Yao Shen

AU - Liu, Yung Ching

AU - Chen, Wei Yu

AU - Jang, Tsrang Neng

AU - Lin, Hsiu Chen

AU - Chen, Chih Ming

AU - Shi, Zhi Yuan

AU - Pan, Sung Ching

AU - Yang, Jia Ling

AU - Kung, Hsiang Chi

AU - Liu, Chun Eng

AU - Cheng, Yu Jen

AU - Chen, Yen Hsu

AU - Lu, Po Liang

AU - Sun, Wu

AU - Wang, Lih Shinn

AU - Yu, Kwok Woon

AU - Chiang, Ping Cherng

AU - Lee, Ming Hsun

AU - Lee, Chun Ming

AU - Hsu, Gwo Jong

AU - Hsueh, Po Ren

PY - 2012/3

Y1 - 2012/3

N2 - The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were <5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.

AB - The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were <5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.

UR - http://www.scopus.com/inward/record.url?scp=84863121492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863121492&partnerID=8YFLogxK

U2 - 10.1128/AAC.05879-11

DO - 10.1128/AAC.05879-11

M3 - Article

C2 - 22155819

AN - SCOPUS:84863121492

SN - 0066-4804

VL - 56

SP - 1414

EP - 1417

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 3

ER -

Liu JW, Ko WC, Huang CH, Liao CH, Lu CT, Chuang YC 等. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. Antimicrobial agents and chemotherapy. 2012 3月;56(3):1414-1417. doi: 10.1128/AAC.05879-11